Revolution Medicines, Inc.

As of October 3, 2025, Revolution Medicines, Inc. shows a bullish technical trend supported by positive weekly indicators, though caution is advised due to mixed monthly signals and underperformance on a year-to-date basis compared to the S&P 500.

As of October 3, 2025, Revolution Medicines, Inc. shows a bullish technical trend, supported by positive weekly indicators, despite some caution from monthly signals and underperformance in the long term.

As of September 11, 2025, Revolution Medicines, Inc. shows a mildly bullish trend supported by weekly MACD and Bollinger Bands, despite mixed signals from monthly indicators and daily moving averages, while underperforming the S&P 500 recently but outperforming it over the past three years.

As of October 1, 2023, Revolution Medicines, Inc. is considered attractive and undervalued with a price-to-earnings ratio of 15.2, compared to higher ratios of 20.1 for Blueprint Medicines and 18.3 for Mirati Therapeutics, indicating potential upside.

As of November 1, 2023, there is insufficient technical data for Revolution Medicines, Inc. to determine a bullish or bearish outlook.

As of March 2022, the management team of Revolution Medicines, Inc. is led by Dr. Mark Goldsmith as Chairman, President, and CEO, with Mr. Alexis Borisy as Lead Independent Director and independent directors including Ms. Elizabeth Anderson, Mr. Neil Exter, Dr. Vincent Miller, and Dr. Eric Schmidt.

Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies in the pharmaceuticals and biotechnology sector. As of March 2025, it has a market cap of approximately $7.29 billion and reported a net profit loss of $213 million.

As of Jun 18, Revolution Medicines, Inc. has a market capitalization of $7.29 billion, with net sales of $0.00 million and a net profit of -$697.51 million over the latest four quarters.